Skip to content

The dual-crosslinked prospective values of COPA for the diagnosis and immunosurveillance in hepatocellular carcinoma

The dual-crosslinked prospective values of COPA for the diagnosis and immunosurveillance in hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114154
Enrollment
Unknown
Registered
2025-12-08
Start date
2024-09-04
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Gold Standard:The gold standard for diagnosing hepatocellular carcinoma in this study was pathological diagnosis, with the reference standard being combined serological markers AFP or PIVKA-II. Pathol
Index test:Serum COPA Detection Method: Sandwich ELISA
Kit Information: Human COPA Protein ELISA Research Kit, Catalog Numbers: MM-64849H1/MM-50499H1. Follow the Standard Operating Procedure (SOP) provided in the kit. Serum AFP and PIVKAII Detection Metho

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
28 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients were included if they had a pathologically confirmed diagnosis of HCC with the primary tumor originating in the liver.

Exclusion criteria

Exclusion criteria: Exclusions applied to patients with severe underlying conditions, incomplete information, or those lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Coatomer Subunit Alpha, COPA;Accuracy;

Secondary

MeasureTime frame
Sensitivity;Specificity;

Countries

China

Contacts

Public ContactYueguo Li

Tianjin Medical University Cancer Institute and Hospital

yli08@tmu.edu.cn+86 186 2222 7869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026